Evidence for S-adenosyl-L-methionine (SAM-e) for the treatment of major depressive disorder

J Clin Psychiatry. 2009;70 Suppl 5:18-22. doi: 10.4088/JCP.8157su1c.04.

Abstract

Despite the increasingly large array of antidepressants available to treat major depressive disorder, patients continue to experience relatively modest response and remission rates. In addition, patients may experience adverse side effects from pharmacotherapy that not only hinder treatment compliance and adherence but, in some cases, may also contribute to increased disability, patient suffering, morbidity, and mortality. In order to enhance treatment efficacy and tolerability, patients and clinicians have become increasingly interested in nonpharmaceutical supplements for treating depression. One of the best-studied of these supplements is S-adenosyl-L-methionine (SAM-e), a naturally occurring molecule present in all living cells and a major methyl group donor in the human body. Controlled trials have found SAM-e to be more efficacious than placebo and equal in efficacy to the tricyclic antidepressants for treating major depressive disorder (MDD) when administered parenterally (either intravenously or intramuscularly). Less evidence supports the use of oral SAM-e, although some trials have demonstrated its efficacy as well. In addition, there is a paucity of evidence examining whether oral forms of SAM-e can be safe, well tolerated, and efficacious when used as adjunctive treatment for antidepressant nonresponders with MDD. Although preliminary data suggest SAM-e may be useful as an adjunctive therapy to antidepressants, controlled studies are needed to confirm or refute these preliminary findings.

Publication types

  • Review

MeSH terms

  • Antidepressive Agents / therapeutic use
  • Clinical Trials as Topic
  • Depressive Disorder, Major / drug therapy*
  • Drug Therapy, Combination
  • Humans
  • S-Adenosylmethionine / therapeutic use*
  • Treatment Outcome

Substances

  • Antidepressive Agents
  • S-Adenosylmethionine